J&J, McKesson and more may reap billions in opioid settlement tax breaks

Four drug companies in settlement talks with states to resolve claims about their role in the opioid epidemic are poised to receive about $1 billion each in tax breaks if they finalized a combined payout totaling more than $26 billion, The Wall Street Journal reported Feb. 12.

Advertisement

The companies are Johnson & Johnson, McKesson, AmerisourceBergen and Cardinal Health.

Below are the amounts the companies both expect to pay as part of the settlement and receive as a tax benefit, according to regulatory filings.

  • McKesson expects to pay $8.1 billion and receive $1.4 billion.
  • AmerisourceBergen expects to pay $6.6 billion and receive $1.1 billion.
  • Cardinal Health expects to pay $6.6 billion and receive $943 million.
  • Johnson & Johnson Expects to pay $5 billion and receive $1 billion.

More articles on opioids:
McKinsey’s hedge fund affiliate may profit from the firm’s $573M opioid settlement
Physician, pharmacist lose licenses for inappropriate opioid dispensing, Medicare fraud
Opioid overdoses up nearly 30% during the pandemic, study says

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.